Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy. (19th August 2022)
- Record Type:
- Journal Article
- Title:
- Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy. (19th August 2022)
- Main Title:
- Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy
- Authors:
- Ali, Alaa M.
Tawfik, Samar S.
Mostafa, Amany S.
Massoud, Mohammed A. M. - Abstract:
- Abstract: Targeted therapy has emerged to be the cornerstone of advanced cancer treatment, allowing for more selectivity and avoiding the common drug toxicity and resistance. Identification of potential targets having vital role in growth and survival of cancer cells got much easier with the aid of the recent advances in high throughput screening approaches. Various protein kinases came into focus as valuable targets in cancer therapy. Meanwhile, benzimidazole‐based scaffolds have gained significant attention as promising protein kinase inhibitors with high potency and varied selectivity. Great diversity of these scaffolds has inspired the medicinal chemists to inspect the effect of structural changes upon inhibitory activity on the molecular level through modeling studies. The present review gathers all the considerable attempts to develop benzimidazole‐based compounds; designed as protein kinase inhibitors with anticancer activity since 2015; that target aurora kinase, CDK, CK2, EGFR, FGFR, and VEGFR‐2; to allow further development and progression regarding benzimidazoles. Abstract : Targeted therapy has emerged to be the cornerstone of advanced cancer treatment, allowing for more selectivity and avoiding drug toxicity and resistance. Various protein kinases came into focus as valuable targets. Benzimidazole‐based scaffolds appeared as promising protein kinase inhibitors with high potency and varied selectivity.
- Is Part Of:
- Chemical biology & drug design. Volume 100:Number 5(2022)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 100:Number 5(2022)
- Issue Display:
- Volume 100, Issue 5 (2022)
- Year:
- 2022
- Volume:
- 100
- Issue:
- 5
- Issue Sort Value:
- 2022-0100-0005-0000
- Page Start:
- 656
- Page End:
- 673
- Publication Date:
- 2022-08-19
- Subjects:
- benzimidazole -- cancer -- inhibitors -- protein kinase -- targeted therapy
Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.14130 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24032.xml